TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG)
a clinical-stage biopharmaceutical company focuses on discovering and
developing novel small molecule therapeutics in oncology and infectious
diseases, today provided an update on the status of its hepatitis B
virus (HBV) clinical program.
The company intends to initiate a
combination single ascending dose/multiple ascending dose clinical
trial, with birinapant as a single agent, in chronic HBV subjects. These
subjects will not be taking other antiviral medication.
In the
single ascending dose phase of the trial, subjects will be given a
single dose of birinapant. The dose of birinapant will be escalated
until at least one of the subjects shows evidence of activity, defined
as an increase in liver transaminases and/or a decline in circulating
viral DNA. At that point the cohort will be expanded and additional
subjects will each receive four weekly administrations, at that dose, of
birinapant. The starting dose of birinapant will be 2.8 mg/m2.
Read more...Labels: birinapant, TetraLogic